GLP-1 loading during elective PCI (GOLD-PCI)
Research type
Research Study
Full title
A phase II study to investigate the protective effects of Glucagon-like Peptide-1 (GLP-1) in patients undergoing elective angioplasty and stenting.
IRAS ID
156665
Contact name
Stephen Hoole
Contact email
Sponsor organisation
Papworth Hospital NHS Foundation Trust
Eudract number
2013-001967-22
Clinicaltrials.gov Identifier
Research summary
Angina is caused by narrowings or blockages within coronary arteries. Coronary angioplasty and stenting is performed for people with angina to improve the blood supply to the heart by placing metal tubes within the artery using balloons. This procedure risks a small amount of damage to heart muscle downstream of the balloon.
Glucagon like peptide 1 (GLP-1) is a naturally occurring hormone secreted by cells in the gut in response to food and stimulates insulin release. In the heart it increases glucose uptake. We are interested in finding out if GLP-1 can protect the heart in people with coronary artery disease. This study will assess whether GLP-1 can protect the heart from damage during coronary angioplasty and stenting.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
14/EE/0218
Date of REC Opinion
16 Jul 2014
REC opinion
Further Information Favourable Opinion